mother post pregnancy

Missed Opportunities For the One In Five With Anal Incontinence After Childbirth

Researchers are calling for improved care and more awareness of injuries that leave over one in five of those giving birth with anal incontinence. Over one in five women will develop anal incontinence in the first five years after having a vaginal birth. Anal incontinence is common and usually caused by trauma to the pelvic floor, nerve damage and anal sphincter injuries. The timing of symptom onset varies; some women experience anal incontinence onset soon after childbirth (which may or may not resolve), while many develop worsening or new symptoms during the menopause. The University of Warwick-led study, with input from the MASIC Foundation (a national charity to support women who have suffered severe injuries during childbirth), identified missed opportunities in getting a diagnosis of anal incontinence, an absence of clear pathways for those who are referred for treatment, and a lack of awareness of the problem among health care professionals and those who have given birth. Read more.

Source: MedicalXpress, June 28, 2023

AUA/SUFU Updates Guideline on Surgical Treatment of Female Stress Urinary Incontinence

The American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) has updated their 2017 clinical practice guideline on the surgical treatment of female stress urinary incontinence (SUI). This amendment is based on their review of 24 studies published through February 2022. No changes were made to the patient evaluation and cystoscopy and urodynamics testing sections and only a minor update was made to patient counseling. Read more.

Source: Renal and Urology News, June 16, 2023

TENA logo Essity

TENA Launches Sensitive Care™ Pads with its SkinComfort Formula™

Today, Essity, a leading global hygiene and health products company and the maker of TENA incontinence and skin care products, announced the launch of Sensitive CareTM Pads, the first ever bladder weakness pads enriched with its gentle SkinComfort Formula. TENA Sensitive Care Pads are now available in-store and online at retailers across the U.S.  Seventy-seven percent of women with bladder weakness claim to experience skin irritation and discomfort while wearing incontinence protection.1 That’s why TENA is addressing intimate skin health with its SkinComfort Formula which incorporates TENA’s skin friendly layer in combination with soft and 100% breathable materials, to help protect intimate skin.   Read more.

Source: PRNewswire, June 13, 2023

drugs for overactive bladder (OAB)

Black Patients Less Likely to Fill Prescriptions For Newer, Safer Urinary Incontinence Drugs

Millions of adults take medications to help relieve symptoms of overactive bladder and reduce episodes of urinary incontinence.  But research linking some of those medications called anticholinergic drugs, such as oxybutynin, to memory loss drove recommendations to treat urinary incontinence with beta-3 agonists, drugs that offer the same benefit but without the risk of cognitive decline.  A new study in JAMA Network Open led by Northwestern Medicine and Duke University School of Medicine shows Black patients are less likely to fill prescriptions for newer, safer urinary incontinence drugs compared to white patients, potentially raising their risk for dementia.  Read more.

Source: Duke University School of Medicine, June 12, 2023

clinical medical

UroMems Announces Results of First Patient in Smart Implant Study to Treat Stress Urinary Incontinence

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the primary endpoints for the initial male patient in its SOPHIA study. SOPHIA is the first-in-man study of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. The results of this clinical study will support design and implementation of UroMems’ pivotal clinical trial in Europe and the U.S. Read more

Source: PRNewswire, June 6, 2023

children pediatric classroom

High Dry Night Rate for Users of New Bedwetting AI Alarm

High compliance users of the new bedwetting alarm, GOGOband, which utilizes real-time heart rate variability analysis and applies artificial intelligence (AI) to create an alarm to wake the user, have a 93 percent dry night rate, according to a study published online April 28 in the Journal of Pediatric Urology.  Israel Franco, M.D., from the Yale University School of Medicine in New Haven, Connecticut, and Jon Coble, from GoGoband Inc. in Richmond, Virginia, evaluated a new bedwetting alarm, GOGOband, and assessed the efficacy in the first 18 months of use. All 54 individuals (mean age, 10.1 years) who used the system for more than 30 nights from Jan. 1, 2020, to June 2021, were included. Read more.

Source: Health Day, May 30, 2023

women india

Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence

Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment. The first-of-its-kind study will examine how women could access treatment within local healthcare delivery systems and in a manner that accommodates cultural norms. Study results will be available in late 2023 and will inform the development of new treatment options based on the Leva® Pelvic Health System, a digital health treatment for urinary incontinence (UI) with published studies supporting its effectiveness, including durable, long-term symptom relief. Read more.

Source: Yahoo! Finance, May 19, 2023

molecules polymers

Megola Completes Successful Pilot Scale-Up Field Testing of its Patent-Pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products

Megola, Inc. (“MGON”, “Company”) a Consortium Group of Health Technologies and Eco-Friendly Product Lines announced the successful completion of its Pilot Scale-up Field Testing with its patent-pending Odor Control (SAPs) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products. The odor control personal hygiene products were provided to a group of incontinent human volunteers in the USA. Superabsorbent Polymer granules (SAP) are used annually in diapers and pads of all types, in a global industry with an annual turnover of more than $100 billion. “It’s been a long time coming but controlling embarrassing odors from incontinence garments and feminine hygiene products is about to become a reality at last….” Read more.

Source: StreetInsider.com, May 8, 2023

Acupuncture

Acupuncture for Women With Overactive Bladder

The most common symptom of an overactive bladder is a sudden, uncontrolled need or urge to urinate; followed by the need to urinate excessively throughout the day and night, independent of fluid intake. In women, causes of overactive bladder are varied, but the common consequence, beyond the physical manifestations, are frustration and embarrassment.  While medications designed to relax the bladder remain a frontline treatment option, research continues to show the potential of nonpharmaceutical options – including acupuncture. Case in point: a 2023 research review that concludes acupuncture is effective and safe for treating overactive bladder. Read more.

Source: Acupunture Today, May/June 2023

Elitone by Elidah

Women’s Health Leader Elidah Launches Game-changing ELITONE URGE Device To Treat Overactive Bladder

Providing the same relief for overactive bladder (OAB) that they’ve become known for in the stress urinary incontinence arena, MedTech Elidah is excited to introduce their newest product, ELITONE URGE (https://elitone.com/products/), the first and only non-intrusive treatment for urge incontinence. This latest device, a natural successor to ELITONE, is specified to treat urgency bladder leaks that afflict 33 million women in the United States alone. ELITONE URGE is an external, non-implanted muscle stimulator that outputs signals to calm the muscles and nerves that cause urgency or OAB leaks. The patented design maximizes comfort and efficacy, while being discreet and wearable under clothes, for the perfect urge incontinence therapy. Read more.

Source: Globe Newswire, May 2, 2023